title: Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
authors.affiliation: Ist Department of Propedeutic Medicine, Athens University School of Medicine, Laikon Hospital, Goudi Athens, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Polyzos
authors.forename: E
authors.initials: E
authors.lastname: Koulentianos
authors.forename: L
authors.initials: L
authors.lastname: Tzianoumis
authors.forename: P
authors.initials: P
authors.lastname: Sfikakis
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001706:Biopsy; D004305:Dose-Response Relationship, Drug; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy* / Q000473:pathology; D009503:Neutropenia / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D016685:Mitomycin